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Getting to Know Your Board Members – 
Andrew Stein
This quarter, the Massachusetts Board of  Registration in 
Pharmacy is highlighting President Andrew “Andy” Stein, 
PharmD, RPh. Andy was one of  the first members appointed 
by Governor Charlie Baker in 2015, and is one of  the two 
independent pharmacy members on the Board.
Andy graduated from Massachusetts College of  Pharmacy 
and Health Sciences in Boston, MA, in 2005, after experienc-
ing the profession through an externship during his senior 
year of  high school. A year after graduating from pharmacy 
school, an opportunity arose to move from his position at a 
chain pharmacy to an independent pharmacy. This paved his 
way to pharmacy ownership. Andy now serves as the manager 
and co-owner of  Bird’s Hill Pharmacy in Needham, MA, a 
neighborhood pharmacy that also provides complex nonsterile 
compounding services.
Andy has commented that even though the Board members’ 
opinions are occasionally at odds with each other, the dialogue 
is always respectful and appreciated. 
“This is probably the best reason for why there is a board 
of pharmacy,” said Andy. “We have representatives from 
different practice settings all bringing together their different 
experiences and even different cultural backgrounds. When 
disagreements occur, we discuss the issue, educate each other 
on our opinions and experiences in the matter, and we vote.” 
Andy’s message to pharmacists is that Board members 
and staff are happy to provide education and guidance. “Feel 
comfortable to reach out . . . with questions, clarifications, 
and/or ideas of what we can do to best guide the practice of 
pharmacy. The Board’s mission is to ensure public safety, not 
be punitive. Attend a meeting to see the process in action!” 
said Andy.
Support of Patients in Recovery
The Board has had recent reports of Suboxone®/ 
buprenorphine stock issues at some pharmacies. Of course, 
no pharmacy wants to be out of  stock of  any product needed 
by a customer, but buprenorphine products are especially 
worrisome, considering their importance for whom they 
are prescribed. A lack of access to medications for opioid 
use disorder, including buprenorphine, may result in patient 
relapse or harm.
Orders for federally designated controlled substances (CS) 
are monitored closely by wholesalers as part of their suspi-
cious orders programs. When a store orders a larger supply 
of a drug than usual, it can trigger a hold on shipping while 
the wholesaler reviews the order to determine its validity. 
Once verified, the order can be sent, but that delay can cause 
a continuity of care issue.
Certainly, changes in your market area may change the 
demand of buprenorphine products, such as the opening of a 
new treatment clinic or increased beds in a facility. It may be 
a good idea to proactively notify your wholesaler in advance 
of ordering a higher-than-usual amount.
Limited or Out-of-Stock Situations
In the interest of continuity of care, dispense a partial sup-
ply of Suboxone®/buprenorphine if you do not have enough 
product to fill the entire prescription.
If you do not have any product, check nearby stores to 
locate it and either transfer the prescription or contact the 
prescriber to send a new prescription to that store.
Naloxone Purchases
Under a statewide standing order, naloxone must be dis-
pensed to anyone asking to purchase it. State law allows 
purchasers to use their own insurance to buy naloxone 
regardless of who the end user may be. The pharmacy 
must make a reasonable effort to determine if  the purchaser’s 
insurance will cover the drug. Instructions for dispensing and 
a copy of  the standing order can be found here.
Identification at Pick Up
Massachusetts law requires identification when picking 
up prescriptions for gabapentin or federally designated 
CS in Schedules II through V. As a reminder, there are 
exceptions allowing you to dispense them to customers with-
out identification.
If  the pharmacist has a reason to believe that the failure to 
dispense the medication would result in a serious hardship 
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prosecution, imprisonment, and revocation of their DEA 
numbers. The agency emphasizes that DEA will never 
contact practitioners by phone to demand money or any 
form of payment. DEA will not request any personal or 
sensitive information by phone, and notification of  le-
gitimate investigation or legal action is made via official 
letter or in person. 
DEA asks anyone who receives a call from a person 
purporting to be a DEA special agent or other law en-
forcement official asking for money to refuse the demand 
and report the threat using the online form or by calling 
877/792-2873. Reporting these calls will assist DEA in 
investigating and stopping this activity. 
FDA Officials Outline 2019 Efforts to 
Improve Quality of Compounded Drugs 
Recognizing the important roles compounded drugs 
can play in patient care, FDA plans to continue its efforts 
to improve the quality of compounded drugs. According 
to a statement posted to the FDA website, these priorities 
include: 
♦ maintaining quality manufacturing compliance,
♦ strengthening and refining regulations on com-
pounding from bulk drug substances,
♦ finalizing the agency’s memorandum of  understand-
ing with the states, and
♦ issuing revised draft guidance for compounding by
hospital and health systems.
“We’ve worked to refine our existing practices, shape 
new policies and increase the frequency of our com-
munications with industry, Congress, states and patients 
concerning our programs,” then-Commissioner Scott 
Gottlieb, MD, and Deputy Commissioner Anna Abram 
said in a statement published on the FDA website. “We 
anticipate that 2019 will be an equally productive year 
for the FDA’s compounding program, with better quality 
continuing to be our top priority as part of our ongoing 
effort . . . to improve the quality of compounded products 
for consumers . . .”
In addition, Gottlieb and Abram’s statement notes that 
the agency will continue to work closely with stakehold-
ers on these steps and any other compounding-related 
measures not outlined in the statement.
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FDA Changes Opioid Labeling to 
Give Providers Better Information on 
Tapering
 Noting that the agency remains focused on striking 
the right balance between policies that reduce the rates of 
opioid addiction while still allowing patients and health 
care providers access to appropriate pain treatments, Food 
and Drug Administration (FDA) has announced required 
changes to the prescribing information for all opioid 
analgesic medications used in the outpatient setting. The 
changes, announced in a Drug Safety Communication, 
provide expanded information to health care providers 
on how to safely decrease the dose in patients who are 
physically dependent on opioids. FDA intends for this 
information to be used when health care providers and 
patients have decided together that a decrease in dose or 
discontinuation of opioids is appropriate. 
“Rapid discontinuation can result in uncontrolled 
pain or withdrawal symptoms. In turn, these symptoms 
can lead patients to seek other sources of opioid pain 
medicines, which may be confused with drug-seeking for 
abuse,” the agency said in the communication. “Patients 
may attempt to treat their pain or withdrawal symptoms 
with illicit opioids, such as heroin, and other substances.”
In addition to these changes, an FDA press release also 
announced that additional policies related to the opioid 
crisis are forthcoming. These include a requirement for 
immediate-release formulations of opioids to be made 
available in fixed-quantity packaging that contain doses 
more typical of what patients may need for common 
acute pain conditions and procedures. The full press 
release is available in the News and Events section of 
the FDA website.
DEA Warns of Scam Calls Targeting 
Pharmacists and Other DEA-Registered 
Providers
Health care providers and other members of  the public 
have reported receiving phone calls from people claiming 
to represent Drug Enforcement Administration (DEA), 
and threatening legal action against them if a large fine 
is not paid immediately over the phone. According to 
a DEA press release, this scam used fake names and 
badge numbers, or the names of  well-known senior 
officials with DEA, and threatened victims with arrest, 
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China Agrees to Stricter Fentanyl 
Production Laws Following Pressure 
From US Lawmakers 
China has announced that all variations of the power-
ful opioid product, fentanyl, will be treated as controlled 
substances (CS). According to a press release from 
Senator Tom Cotton, the announcement came after a 
bipartisan group of  United States lawmakers, including 
Cotton, introduced Senate Bill 1044, a bill designed to 
apply pressure to the Chinese government to make all 
forms of  synthetic opioids illegal and to provide US law 
enforcement with more tools and resources to go after 
illicit traffickers in China, Mexico, and other countries. 
“Combating the flow of  illicit fentanyl into our coun-
try is imperative in the fight to save American lives 
from the opioid crisis,” Senate Minority Leader Chuck 
Schumer said in the press release. “We must hold China 
accountable for their role in the fentanyl trade. China’s 
new regulation to make all fentanyl categories illegal is 
an important step and the administration deserves praise 
for their efforts to secure this change. However, we have 
to demonstrate that we will demand China enforce these 
laws and take strong action against opioid traffickers.”
In a December meeting with President Donald Trump, 
China’s President Xi Jinping promised to classify fen-
tanyl as a CS following a 2018 report by the US-China 
Economic and Security Review Commission that found 
China to be “the largest source of  illicit fentanyl and 
fentanyl-like substances” in the US, according to a report 
from NPR. The latest increase in opioid-related overdose 
deaths has been largely attributed to the availability of 
illegally manufactured fentanyl.
Two Lots of Transdermal Fentanyl 
Patches Recalled Due to Product 
Mislabeling
Alvogen, Inc, of  Pine Brook, NJ, is recalling two lots 
of Fentanyl Transdermal System 12 mcg/h transdermal 
patches to the consumer level after a small number of 
cartons were found to contain 50 mcg/h patches. Though 
the 50 mcg/h patches are individually labeled correctly, 
accidental application of  the higher dosage patch instead 
of the prescribed 12 mcg/h patch could result in serious, 
life-threatening, or fatal respiratory depression. The 
company has not received any reports of adverse events 
related to this issue.
The company is notifying its distributors and direct 
customers by certified letter and is arranging for the return 
and replacement of  all recalled products. Pharmacies 
are asked to stop dispensing any product subject to the 
recall. Consumers that have affected products should im-
mediately remove any patch currently in use and contact 
their health care provider. Patients with unused product 
should return it to the point of  purchase for replacement. 
Additional information on the recall, including the 
affected lot numbers and customer service contact infor-
mation, is available in a press release posted to the FDA 
website. Adverse reactions and quality problems can be 
reported to the FDA MedWatch Safety Information and 
Adverse Event Reporting Program.
FDA Releases Toolkit to Help Promote 
Safe Opioid Disposal
FDA has made a new resource available for consumers 
and health care providers to help promote and educate 
individuals about how to safely dispose of unused opi-
oids. The free Safe Opioid Disposal – Remove the Risk 
Outreach Toolkit includes video, radio, and print public 
service announcements, social media graphics and posts, 
fact sheets, drop-in content, and website badges that 
health care providers and other interested individuals and 
organizations can use to promote the message of opioid 
safety. The toolkit and its resources can be accessed on 
the Ensuring Safe Use of  Medicine section of the FDA 
website.
An additional resource available to help consumers 
find disposal kiosks available year round is the National 
Association of Boards of Pharmacy® (NABP®) Drug 
Disposal Locator Tool, available in the AWARXE® Pre-
scription Drug Safety section of  the NABP website, www 
.nabp.pharmacy/initiatives/AWARxE. With more than 
6,500 disposal sites in the continually updated database, 
consumers can enter location information to find the 
nearest disposal sites to them using a map. 
Additional information about the FDA campaign can 
be found at https://www.fda.gov/drugs/buying-using-
medicine-safely/ensuring-safe-use-medicine.
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for the patient, it may be dispensed without identification if 
the reason is documented and either of the following condi-
tions are met.
1. The patient or agent of the patient prints his or her name 
and address on the back of the prescription and signs 
his or her name; or 
2. The patient or agent of the patient provides an electronic 
signature in the case of  an electronic prescription.
Further instructions can be found in the PMP Data 
Submission Dispenser Guide. 
‘Locked-In’ Patients
You are probably aware that some patients may be re-
stricted to receiving medications from only one specific 
pharmacy. Once that specific pharmacy is designated as the 
primary location, no other pharmacy may dispense medica-
tions, especially federally designated CS in Schedules II 
through V.  If a claim is adjudicated to the health plan by a 
pharmacy that is not the designated location for a locked-in 
patient, a rejection message is returned.
If  a medication is urgently needed for the treatment of an 
acute injury or serious condition, and the primary pharmacy 
is either closed or out of stock, the locked-in patient may 
receive medications at an alternate location with an over-
ride. If an override cannot be obtained from the health plan 
(eg, the agency is closed), and it is the professional opinion 
of the pharmacist that the patient’s health or safety would 
be jeopardized without treatment, a limited supply may be 
dispensed. Detailed documentation and notification to the 
health plan must be completed as soon as possible.
Please make a professional, good faith effort to try to help 
these patients who may be vulnerable as they work toward 
recovery.
Electronic Prescriptions for CS
Currently, prescriptions may be accepted at Massachusetts 
pharmacies through various methods, such as paper, fax, and 
electronic prescribing. In order to help combat the current 
epidemic of opioid abuse via paper-based prescriptions, only 
electronic prescriptions will be accepted at pharmacies for 
all CS in Schedules II through VI, effective January 1, 2020.
Exceptions to the new law include veterinary prescrip-
tions, out-of-state prescriptions, instances where electronic 
prescribing is not available due to temporary technological 
or electrical failure, emergency prescriptions as defined by 
the commissioner of the Massachusetts Department of Public 
Health, and in cases where the prescriber has been issued a 
temporary waiver.
Other exceptions have been proposed by the Massachu-
setts Drug Control Program in the draft regulations of 105 
Code of  Massachusetts Regulations (CMR) 721.000. Public 
comments were accepted for these amendments through 
July 2, 2019. 
Institutional Sterile Compounders – 
Voluntary Inspections
In anticipation of the finalization of 247 CMR 6.00: 
Licensure of  Pharmacies, the Board is seeking institutional 
sterile compounding facilities to voluntarily participate in 
Board inspections before the regulations actually go into 
effect. This is an opportunity for potential licensees to get 
an early start in determining the compliance of their sterile 
compounding areas and to have an opportunity to discuss 
issues and ask the inspectors questions.
The tool that will be used for the inspections is available 
on the Board’s website, and investigators would schedule the 
inspection for a mutually agreeable time. If  the sterile com-
pounding area is deemed compliant based on this inspection, 
a license may be issued as a result of it when the licensing 
regulations are promulgated. The voluntary inspections will 
be scheduled on a first-come, first-served basis. If  interested, 
please contact Pharmacy Investigator Nathan Van Allen via 
email at nathan.vanallen@massmail.state.ma.us. 
Did You Know?
 ♦ As a reminder, all pharmacies licensed by the Board 
must be compliant with all chapters of  United States 
Pharmacopeia (USP). Newly revised USP General 
Chapters <795>, <797>, and <800> will go into effect 
on December 1, 2019.
 ♦ Dr Anita Young, EdD, RPh, director of continuing phar-
macy education at Northeastern University, has been 
named the 2019 honorary president of  the National 
Association of Boards of  Pharmacy® (NABP®) for her 
commitment to the protection of public health and her in-
volvement with NABP and the state boards of pharmacy. 
 ♦ Timothy D. Fensky, RPh, DPh, FACA, a member and 
past president of the Massachusetts Board of Registration 
in Pharmacy, has been elected as president-elect of  the 
2019-2020 NABP Executive Committee. He is the chief 
operating officer of  Sullivan’s Health Care.
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